EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors



Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors



Official Gazette of the United States Patent & Trademark Office Patents 1188(1): 442, July 2




(PDF emailed within 1 workday: $29.90)

Accession: 034065398

Download citation: RISBibTeXText



Related references

Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. The Journal of Cell Biology 144(2): 3-84, 1999

Alpha-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders. Official Gazette of the United States Patent & Trademark Office Patents 1260(2), July 9, 2002

Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis and Rheumatism 52(7): 2159-2167, 2005

Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors. JAMA Internal Medicine 175(12): 1990-1992, 2016

Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorganic & Medicinal Chemistry Letters 22(1): 138-143, 2012

Antigen discovery in chronic human inflammatory central nervous system disease: panning phage-displayed antigen libraries identifies the targets of central nervous system-derived IgG in subacute sclerosing panencephalitis. Journal of Immunology 167(10): 6009-6014, 2001

Compositions and methods for the treatment of Alzheimers disease, central nervous system injury, and inflammatory diseases. Official Gazette of the United States Patent & Trademark Office Patents 1243(3), Feb 20, 2001

Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. American Journal of Pathology 152(3): 729-741, 1998

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). Journal of Neural Transmission 121(5): 469-477, 2014

Different expression patterns of matrix metalloproteinases in inflammatory demyelinating diseases of the central and peripheral nervous system. Journal of Neuroimmunology 90(1): 22, Sept 1, 1998

Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Research 1022(1-2): 1-11, 2004

Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. Journal Of Neuroimmunology. 69(1-2): 141-149, 1996

Evaluation of matrix metalloproteinases 2 and 9 activity in cerebrospinal fluid of dogs with non-inflammatory diseases of the central nervous system. Veterinary Research Communications 30(Suppl. 1): 317-319, 2006

Matrix metalloproteinases exhibit different expression patterns in inflammatory demyelinating diseases of the central and peripheral nervous system. Annals of the New York Academy of Sciences 878: 567-570, 1999